231 related articles for article (PubMed ID: 21533174)
1. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.
Sjödahl G; Lauss M; Gudjonsson S; Liedberg F; Halldén C; Chebil G; Månsson W; Höglund M; Lindgren D
PLoS One; 2011 Apr; 6(4):e18583. PubMed ID: 21533174
[TBL] [Abstract][Full Text] [Related]
2. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Myers AP; Filiaci VL; Zhang Y; Pearl M; Behbakht K; Makker V; Hanjani P; Zweizig S; Burke JJ; Downey G; Leslie KK; Van Hummelen P; Birrer MJ; Fleming GF
Gynecol Oncol; 2016 Apr; 141(1):43-8. PubMed ID: 27016228
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
7. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
9. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
12. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.
Chakraborty S; Mohiyuddin SM; Gopinath KS; Kumar A
BMC Cancer; 2008 Jun; 8():163. PubMed ID: 18538015
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
16. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
18. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Platt FM; Hurst CD; Taylor CF; Gregory WM; Harnden P; Knowles MA
Clin Cancer Res; 2009 Oct; 15(19):6008-17. PubMed ID: 19789314
[TBL] [Abstract][Full Text] [Related]
20. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
